NCT03544125View on ClinicalTrials.gov

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

August 7, 2018

Study Completion Date

November 18, 2020

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativePrognostic Stage IV Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Interventions
BIOLOGICAL

Durvalumab

Given IV

DRUG

Olaparib

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Prospect Creek Foundation

UNKNOWN

lead

OHSU Knight Cancer Institute

OTHER

NCT03544125 - Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter